Tanja Obradovic: Two practice-changing trials of Keytruda within Presidential Symposium of ESMO24
Tanja Obradovic shared on LinkedIn:
“ESMO 2024 will have two practice-changing trials of Keytruda (Pembrolizumab) presented within Presidential Symposium. We’ll see first time OS results from Phase III Keynote-522 trial of Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as single agent adjuvant in TNBC patients with high-risk early-stage disease.
Also, OS from the Phase III Keynote-A18 trial evaluating Keytruda in combination with concurrent chemoradiotherapy (CRT) as treatment for patients with high-risk locally advanced cervical cancer. Amazing success for Merck Women’s cancer team and testament to outstanding leadership of immunooncology expert Gursel Aktan and her absolute commitment to cancer patients! Congratulations!”
Read Further.
Source: Tanja Obradovic/LinkedIn
More posts featuring Tanja Obradovic on oncodaily.com
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023